Cargando…

Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report

BACKGROUND: The immune response to SARS-CoV-2 virus, the cause of COVID-19, is complex. Antibody mediated responses are important for viral clearance but may also drive hyperinflammation in severe COVID-19. We present a case of an individual with a genetic inability to produce antibodies and severe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyström, Katarina, Hjorth, Maria, Fust, Ramona, Nilsdotter-Augustinsson, Åsa, Larsson, Marie, Niward, Katarina, Nyström, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996199/ https://www.ncbi.nlm.nih.gov/pubmed/35410137 http://dx.doi.org/10.1186/s12879-022-07323-4

Ejemplares similares

SARS-CoV-2 Specific Antibody Response and T Cell-Immunity in Immunocompromised Patients up to Six Months Post COVID: A Pilot Study
por: Sjöwall, Johanna, et al.
Publicado: (2022)

Long Term Norovirus Infection in a Patient with Severe Common Variable Immunodeficiency
por: Ottosson, Loa, et al.
Publicado: (2022)

T cell perturbations persist for at least 6 months following hospitalization for COVID-19
por: Govender, Melissa, et al.
Publicado: (2022)

Fatigue Is Common in Immunoglobulin G Subclass Deficiency and Correlates With Inflammatory Response and Need for Immunoglobulin Replacement Therapy
por: Wågström, Per, et al.
Publicado: (2022)

Major alterations to monocyte and dendritic cell subsets lasting more than 6 months after hospitalization for COVID-19
por: Hopkins, Francis R., et al.
Publicado: (2023)

Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency
por: Honjo, Kazuhito, et al.
Publicado: (2020)

Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19
por: Hopkins, Francis R., et al.
Publicado: (2023)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Enocsson, Helena, et al.
Publicado: (2021)

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature
por: Delgado-Fernández, Marcial, et al.
Publicado: (2022)

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature
por: Delgado-Fernández, Marcial, et al.
Publicado: (2022)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Viral load at hospitalization is an independent predictor of severe COVID‐19
por: Waller, Hjalmar, et al.
Publicado: (2022)

Lower activation of caspase-1 by Staphylococcus epidermidis isolated from prosthetic joint infections compared to commensals
por: Månsson, Emeli, et al.
Publicado: (2018)

Same Organism, Different Phenotype - Are Phenotypic Criteria Adequate In Coagulase-Negative Staphylococcal Orthopaedic Implant-Associated Infections?
por: Tevell, Staffan, et al.
Publicado: (2019)

Comparative genomics of Staphylococcus epidermidis from prosthetic-joint infections and nares highlights genetic traits associated with antimicrobial resistance, not virulence
por: Månsson, Emeli, et al.
Publicado: (2021)

Discovering aspects of health—experiences of a web‐based health diary among adults with primary immunodeficiency
por: Petersson, Christina, et al.
Publicado: (2018)

Staphylococcus epidermidis isolates from nares and prosthetic joint infections are mupirocin susceptible
por: Salih, Lavin, et al.
Publicado: (2018)

HIV-Infected Individuals on ART With Impaired Immune Recovery Have Altered Plasma Metabolite Profiles
por: Nyström, Sofia, et al.
Publicado: (2021)

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
por: Rnjak, D., et al.
Publicado: (2021)

Evaluation of SARS-CoV-2 rapid antigen diagnostic tests for saliva samples
por: Hagbom, Marie, et al.
Publicado: (2022)

Staphylococcus capitis isolated from prosthetic joint infections
por: Tevell, S., et al.
Publicado: (2016)

Efficacy of convalescent plasma for the treatment of severe influenza
por: Xu, Zhiheng, et al.
Publicado: (2020)

Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini, Massimo, et al.
Publicado: (2021)

Methicillin-Resistant Staphylococcus epidermidis Lineages in the Nasal and Skin Microbiota of Patients Planned for Arthroplasty Surgery
por: Månsson, Emeli, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections
por: Littorin, C., et al.
Publicado: (2017)

Editorial: Updates on convalescent plasma and monoclonal antibody therapies for infectious disease in patients with primary immunodeficiency
por: Condino-Neto, Antonio, et al.
Publicado: (2022)

HUMORAL ANTIBODIES AND RESISTANCE OF VACCINATED AND CONVALESCENT MONKEYS TO POLIOMYELITIS VIRUS
por: Sabin, Albert B., et al.
Publicado: (1936)

Humoral and cellular response in convalescent COVID-19 lupus patients
por: Solé, Cristina, et al.
Publicado: (2022)

Alteration of Bacterial Communities in Anterior Nares and Skin Sites of Patients Undergoing Arthroplasty Surgery: Analysis by 16S rRNA and Staphylococcal-Specific tuf Gene Sequencing
por: Iversen, Søren, et al.
Publicado: (2020)

SARS‐CoV‐2‐specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma
por: Lindemann, Monika, et al.
Publicado: (2021)

Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
por: Ekqvist, David, et al.
Publicado: (2022)

Effectiveness of convalescent plasma therapy in severe COVID-19 patients
por: Duan, Kai, et al.
Publicado: (2020)

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2020)

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: De Santis, Gil C., et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Efficacy of convalescent plasma therapy in severe COVID-19 patients
por: Akay Cizmecioglu, Hilal, et al.
Publicado: (2021)

Rituximab: Humoral immunodeficiency: case report
Publicado: (2021)

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
por: Dewald, Felix, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sqr5gjv6h85th82e46r06es92v